Experimental Therapeutics for Dystonia

Neurotherapeutics

Volumn 5, Issue 2, 2008, Pages 198-209

  Jinnah, H A ^a   Hess, Ellen J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

animal models; drug discovery; Dystonia; pathogenesis; therapy

Indexed keywords

ACETYLCHOLINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN; CARISOPRODOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOBENZAPRINE; LEVODOPA; METAXALONE; METHOCARBAMOL; MEXILETINE; TETRABENAZINE; TIZANIDINE;

ARTICLE; BIOCHEMISTRY; BRAIN DEPTH STIMULATION; CEREBRAL PALSY; CLINICAL RESEARCH; COGNITIVE DEFECT; CONSTIPATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SCREENING; DYSTONIA; EMPIRICISM; EXPERIMENTAL ANIMAL; EXPERIMENTAL THERAPY; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC MODEL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MUSCLE ATONIA; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; SHORT TERM MEMORY; SIDE EFFECT; SURGICAL TECHNIQUE; URINE RETENTION; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG EVALUATION, PRECLINICAL; DYSTONIA; HUMANS;

EID: 41249089604     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.01.001     Document Type: Article

References (98)

1. Fahn S. The varied clinical expressions of dystonia. Neurol Clinics 2 (1984) 541-554
2. Fahn S. Concept and classification of dystonia. Adv Neurol 50 (1988) 1-8
3. Defazio G. Epidemiology of primary and secondary dystonia. In: Stacy M.A. (Ed). Handbook of dystonia (2007), Informa Healthcare USA, New York 11-20
4. Sanger T.D., Delgado M.R., Gaebler-Spira D., Hallett M., Mink J.W., and Task Force on Childhood Motor Disorders. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 111 (2003) e89-e97
5. Kyllerman M., Bager B., Bensch J., Bille B., Olow I., and Voss H. Dyskinetic cerebral palsy. I. Clinical categories, associated neurological abnormalities and incidences. Acta Pediatr Scand 71 (1982) 543-550
6. Albright A.L., Barry M.J., Shafton D.H., and Ferson S.S. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 43 (2001) 652-657
7. Tolosa E., and Compta Y. Dystonia in Parkinson's disease. J Neurol 253 Suppl 7 (2006) VII7-VII13
8. Jankovic J., and Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord 8 (2001) 109-121
9. Jankovic J. Treatment of dystonia. Lancet Neurol 5 (2006) 864-872
10. Albanese A., Barnes M.P., Bhatia K.P., et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES task force. Eur J Neurol 13 (2006) 433-444
11. Balash Y., and Giladi N. Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 11 (2004) 361-370
12. Tarsy D., and Simon D.K. Dystonia. N Engl J Med 355 (2006) 818-829
13. Arce C.A. Selective denervation in cervical dystonia. In: Stacy M.A. (Ed). Handbook of dystonia (2007), Informa Healthcare USA, New York 381-392
14. Walker R.H., Danisi F.O., Swope D.M., Goodman R.R., Germano I.M., and Brin M.F. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 15 (2000) 1242-1247
15. Ostrem J.L., and Starr P.A. Treatment of dystonia with deep brain stimulation. Neurotherapeutics 5 (2008) 319-329
16. Pisani A., Bernardi G., Ding J., and Surmeier D.J. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30 (2007) 545-553
17. Jinnah H.A., Richter A., Mink J.W., et al. Animal models for drug discovery in dystonia. Expert Opin Drug Discov 3 (2008) 83-97
18. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28 (2005) 57-87
19. Cookson M.R. The biochemistry of Parkinson's disease. Annu Rev Biochem 74 (2005) 29-52
20. Mochizuki H., Yasuda T., and Mouradian M.M. Advances in gene therapy for movement disorders. Neurotherapeutics 5 (2008) 260-269
21. LeWitt P.A., and Taylor D.C. Protection against Parkinson's disease progression: clinical experience. Neurotherapeutics 5 (2008) 210-225
22. Newman M.B., and Bakay R.A.E. Therapeutic potentials of human embryonic stem cells in Parkinson's disease. Neurotherapeutics 5 (2008) 237-251
23. Limousin P., and Martinez-Torres I. Deep brain stimulation for Parkinson's disease. Neurotherapeutics 5 (2008) 309-319
24. Gross R. What happened to posteroventral pallidotomy for Parkinson's disease and dsytonia?. Neurotherapeutics 5 (2008) 281-293
25. Segawa M., Nomura Y., and Nishiyama N. Dopa-responsive dystonia. In: Stacy M.A. (Ed). Handbook of dystonia (2007), Informa Healthcare USA, New York 219-244
26. Jinnah H.A., and Hess E.J. A new twist on the anatomy of dystonia: the basal ganglia and the cerebellum. Neurology 67 (2006) 1740-1741
27. McGeer E.G., and McGeer P.L. The dystonias. Can J Neurol Sci 15 (1988) 447-483
28. Marks Jr. W.J. Brain surgery for dystonia. In: Stacy M.A. (Ed). Handbook of dystonia (2007), Informa Healthcare USA, New York 393-406
29. Ozelius L.J., Hewett J.W., Page C.E., et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 17 (1997) 40-48
30. Goodchild R.E., and Dauer W.T. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci U S A 101 (2004) 847-853
31. Torres G.E., Sweeney A.L., Beaulieu J.M., Shashidharan P., and Caron M.G. Effect of torsinA on membrane proteins reveals a loss of function and a dominant-negative phenotype of the dystonia-associated ΔE-torsinA mutant. Proc Natl Acad Sci U S A 101 (2004) 15650-15655
32. Misbahuddin A., Placzek M.R., Taanman J.W., et al. Mutant torsinA, which causes early-onset primary torsion dystonia, is redistributed to membranous structures enriched in vesicular monoamine transporter in cultured human SH-SY5Y cells. Mov Disord 20 (2005) 432-440
33. Balcioglu A., Kim M.O., Sharma N., Cha J.H., Breakefield X.O., and Standaert D.G. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 102 (2007) 783-788
34. Hewett J.W., Tannous B., Niland B.P., et al. Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A 104 (2007) 7271-7276
35. Hewett J.W., Zeng J., Niland B.P., Bragg D.C., and Breakefield X.O. Dystonia-causing mutant torsinA inhibits cell adhesion and neurite extension through interference with cytoskeletal dynamics. Neurobiol Dis 22 (2006) 98-111
36. Pisani A., Martella G., Tscherter A., et al. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiol Dis 24 (2006) 318-325
37. Hewett J., Gonzalez-Agosti C., Slater D., et al. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet 9 (2000) 1403-1413
38. McNaught K.S., Kapustin A., Jackson T., et al. Brainstem pathology in DYT1 primary torsion dystonia. [Erratum in: Ann Neurol 2004;56:750]. Ann Neurol 56 (2004) 541-547
39. Goodchild R.E., Kim C.E., and Dauer W.T. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 48 (2005) 923-932
40. Gonzalez-Alegre P., and Paulson H.L. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J Neurosci 17 (2004) 2593-2601
41. Eidelberg D., Moeller J.R., Antonini A., et al. Functional brain networks in DYT1 dystonia. Ann Neurol 44 (1998) 303-312
42. Gonzalez-Alegre P., Bode N., Davidson B.L., and Paulson H.L. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 25 (2005) 10502-10509
43. Caldwell G.A., Cao S., Sexton E.G., Gelwix C.C., Bevel J.P., and Caldwell K.A. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 12 (2003) 307-319
44. Cao S., Gelwix C.C., Caldwell K.A., and Caldwell G.A. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 25 (2005) 3801-3812
45. McLean P.J., Kawamata H., Shariff S., et al. TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem 83 (2002) 846-854
46. Clarimon J., Asgeirsson H., Singleton A., et al. Torsin A haplotype predisposes to idiopathic dystonia. Ann Neurol 57 (2005) 765-767
47. Kamm C., Asmus F., Mueller J., et al. Strong genetic evidence for association of TOR1A/TOR1B with idiopathic dystonia. Neurology 67 (2006) 1857-1859
48. Sibbing D., Asmus F., König I.R., et al. Candidate gene studies in focal dystonia. Neurology 61 (2003) 1010-1097
49. Hague S., Klaffke S., Clarimon J., et al. Lack of association with torsinA haplotype in German patients with sporadic dystonia. Neurology 66 (2006) 951-952
50. Clarimon J., Brancati F., Peckham E., et al. Assessing the role of DRD5 and DYT1 in two different case-control series with primary blepharospasm. Mov Disord 22 (2006) 162-166
51. Perlmutter J.S., and Mink J.W. Dysfunction of dopaminergic pathways in dystonia. Adv Neurol 94 (2004) 163-170
52. Jinnah H.A., Visser J.E., Harris J.C., et al., Lesch-Nyhan Disease International Study Group. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 129 (2006) 1201-1217
53. Visser J.E., Bär P.R., and Jinnah H.A. Lesch-Nyhan syndrome and the basal ganglia. Brain Res Brain Res Rev 32 (2000) 449-475
54. Boyce S., Clarke C.E., Luquin R., et al. Induction of chorea and dystonia in Parkinsonian primates. Mov Disord 5 (1990) 3-7
55. Perlmutter J.S., Tempel L.W., Black K.J., et al. MPTP induces dystonia and parkinsonism: clues to the pathophysiology of dystonia. Neurology 49 (1997) 1432-1438
56. Troiano A.R., and Stoessl A.J. Neuroimaging in dystonia. In: Stacy M.A. (Ed). Handbook of dystonia (2007), Informa Healthcare USA, New York 93-106
57. Augood S.J., Hollingsworth Z., Albers D.S., et al. Dopamine transmission in DYT1 dystonia. Adv Neurol 94 (2004) 53-60
58. Cardoso F. Drug-induced dystonia. In: Stacy M.A. (Ed). Handbook of dystonia (2007), Informa Healthcare USA, New York 267-276
59. Nemeth A.H. The genetics of primary dystonias and related disorders. Brain 125 (2002) 695-721
60. Sudarsky L., Plotkin G.M., Logigian E.L., and Johns D.R. Dystonia as a presenting feature of the 3243 mitochondrial DNA mutation. Mov Disord 14 (1999) 488-491
61. Head R.A., de Goede C.G., Newton R.W., et al. Pyruvate dehydrogenase deficiency presenting as dystonia in childhood. Dev Med Child Neurol 46 (2004) 710-712
62. McFarland R., Chinnery P.F., Blakely E.L., et al. Homoplasmy, heteroplasmy, and mitochondrial dystonia. Neurology 69 (2007) 911-916
63. Simon D.K., Friedman J., Breakefield X.O., et al. A heteroplasmic mitochondrial complex I gene mutation in adult-onset dystonia. Neurogenetics 4 (2003) 199-205
64. Swerdlow R.H., and Wooten G.F. A novel deafness/dystonia peptide gene mutation that causes dystonia in female carriers of Mohr-Tranebjaerg syndrome. Ann Neurol 50 (2001) 537-540
65. Kim H.T., Edwards M.J., Tyson J., Quinn N.P., Bitner-Glindzicz M., and Bhatia K.P. Blepharospasm and limb dystonia caused by Mohr-Tranebjaerg syndrome with a novel splice site mutation in the deafness/dystonia peptide gene. Mov Disord 22 (2007) 1328-1331
66. Müller-Vahl K.R., Kolbe H., Egensperger R., and Dengler R. Mitochondriopathy, blepharospasm, and treatment with botulinum toxin. Muscle Nerve 23 (2000) 647-648
67. He F., Zhang S., Qian F., and Zhang C. Delayed dystonia with striatal CT lucencies induced by a mycotoxin (3-nitropropionic acid). Neurology 45 (1995) 2178-2183
68. Palfi S., Leventhal L., Goetz C.G., et al. Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. Mov Disord 15 (2000) 524-530
69. Schapira A.H., Warner T., Gash M.T., Cleeter M.W., Marinho C.F., and Cooper J.M. Complex I function in familial and sporadic dystonia. Ann Neurol 41 (1997) 556-559
70. Benecke R., Strumper P., and Weiss H. Electron transfer complex I defect in idiopathic dystonia. Ann Neurol 32 (1992) 683-686
71. Quartarone A., Siebner H.R., and Rothwell J.C. Task-specific hand dystonia: can too much plasticity be bad for you?. Trends Neurosci 29 (2006) 192-199
72. Rothwell J.C., and Huang Y.Z. Systems-level studies of movement disorders in dystonia and Parkinson's disease. Curr Opin Neurobiol 13 (2003) 691-695
73. Carbon M., Ghilardi M.F., Argyelan M., Dhawan V., Bressman S.B., and Eidelberg D. Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. Brain 131 (2008) 146-154
74. Hallett M. Pathophysiology of dystonia. J Neural Transm Suppl 70 (2006) 485-488
75. Shashidharan P., Sandu D., Potla U., et al. Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet 14 (2005) 125-133
76. Grundmann K., Reischmann B., Vanhoutte G., et al. Overexpression of human wildtype torsinA and human ΔGAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol Dis 27 (2007) 190-206
77. Sharma N., Baxter M.G., Petravicz J., et al. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci 25 (2005) 5351-5355
78. Jinnah H.A., Hess E.J., LeDoux M.S., et al. Rodent models for dystonia research: characteristics, evaluation, and utility. Mov Disord 20 (2005) 283-292
79. Duchen L.W. Dystonia musculorum: an inherited disease of the nervous system in the mouse. Adv Neurol 14 (1976) 353-365
80. Lorden J.F., McKeon T.W., Baker H.J., et al. Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. J Neurosci 4 (1984) 1925-1932
81. Fletcher C.F., Lutz C.M., O'Sullivan T.N., et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 87 (1996) 607-617
82. Doyle J., Ren X., Lennon G., and Stubbs L. Mutations in the Cacnl1a4 calcium channel gene are associated with seizures, cerebellar degeneration, and ataxia in tottering and leaner mutant mice. Mamm Genome 8 (1997) 113-120
83. Giffin N.J., Benton S., and Goadsby P.J. Benign paroxysmal torticollis of infancy: four new cases and linkage to CACNA1A mutation. Dev Med Child Neurol 44 (2002) 490-493
84. Spacey S.D., Materek L.A., Szczygielski B.I., et al. Two novel CACNA1A gene mutations associated with episodic ataxia type 2 and interictal dystonia. Arch Neurol 62 (2005) 314-316
85. Fureman B.E., Jinnah H.A., and Hess E.J. Triggers of paroxysmal dyskinesias in the calcium channel mouse mutant tottering. Pharmacol Biochem Behav 73 (2002) 631-637
86. Shirley T.L., Rao L.M., Hess E.J., and Jinnah H.A. Paroxysmal dyskinesias in mice. Mov Disord 23 (2007) 259-264
87. Löscher W., Fisher Jr. J.E., Schmidt D., Fredow G., Hönack D., and Iturrian W.B. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia?. Mov Disord 4 (1989) 219-232
88. Richter A., and Löscher W. Pathology of idiopathic dystonia: findings from genetic animal models. Prog Neurobiol 54 (1998) 633-677
89. Pizoli C.E., Jinnah H.A., Billingsley M.L., and Hess E.J. Abnormal cerebellar signaling induces dystonia in mice. J Neurosci 22 (2002) 7825-7833
90. Alvarez-Fischer D., Grundmann M., Lu L., Moller C., Oertel W.H., and Bandmann O. Gene expression studies in a novel rat dystonia model. Mov Disord 19 (2004) S98 (abstract)
91. Fernagut P.O., Diguet E., Stefanova N., et al. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Neuroscience 114 (2002) 1005-1017
92. Ouary S., Bizat N., Altairac S., et al. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: implications for neuroprotection studies. Neuroscience 97 (2000) 521-530
93. Jinnah H.A., Sepkuty J.P., Ho T., et al. Calcium channel agonists and dystonia in the mouse. Mov Disord 15 (2000) 542-551
94. Blake B.L., Muehlmann A.M., Egami K., Breese G.R., Devine D.P., and Jinnah H.A. Nifedipine suppresses self-injurious behavior in animals. Dev Neurosci 29 (2007) 241-250
95. Cenci M.A., and Lundblad M. Utility of 6-hydroxydopamine lesioned rats in preclinical screening of novel treatments for Parkinson disease. In: LeDoux M. (Ed). Animal models of movement disorders (2005), Elsevier, Amsterdam 193-208
96. Jinnah H.A., and Hess E.J. The assessment of movement disorders in rodents. In: LeDoux M. (Ed). Animal models of movement disorders (2005), Elsevier Academic Press, San Diego 55-71
97. Comella C.L., Leurgans S., Wuu J., Stebbins G.T., Chmura T., and Dystonia Study Group. Rating scales for dystonia: a multicenter trial. Mov Disord 18 (2003) 303-312
98. Kupferberg H.J. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia 30 Suppl 1 (1989) S51-S56